Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects

D Kerr, I A MacDonald, S R Heller, R B Tattersall, D Kerr, I A MacDonald, S R Heller, R B Tattersall

Abstract

1. The effect of 1 week of treatment with propranolol LA (160 mg), atenolol (100 mg) and metoprolol CR (100 mg) on awareness of and the physiological responses to moderate hypoglycaemia were compared with placebo using a randomised, cross-over design in 12 healthy volunteers. 2. All three beta-adrenoceptor antagonists reduced resting heart rate, systolic blood pressure and heart rate responses to submaximal exercise compared with placebo. 3. Under hyperinsulinaemic (60 mu m-2 min-1) clamp conditions, at a blood glucose of 2.5 mmol l-1, atenolol prevented the rise in systolic and atenolol and metoprolol CR prevented the fall in diastolic blood pressure usually associated with hypoglycaemia. At this level of hypoglycaemia, the expected increase in heart rate was inhibited by atenolol but not metoprolol CR. Pre-treatment with propranolol LA resulted in a significant pressor response and a bradycardia during hypoglycaemia. In addition the normal increase in finger tremor was abolished by propranolol LA. 4. During hypoglycaemia all three beta-adrenoceptor blockers augmented sweating compared with placebo but hypoglycaemic symptoms, awareness and slowing of reaction time were the same with drugs and placebo. 5. The rise in plasma adrenaline and other counter-regulatory hormones during hypoglycaemia was enhanced by beta-adrenoceptor blockade. 6. We conclude that beta-adrenoceptor antagonists modify the physiological and hormonal responses to, but do not adversely affect awareness of, moderate hypoglycaemia in healthy volunteers.

References

    1. Lancet. 1966 Dec 24;2(7478):1386-8
    1. Diabetologia. 1989 Apr;32(4):249-54
    1. Metabolism. 1970 Jul;19(7):547-52
    1. Br J Dermatol. 1971 Oct;85(4):363-7
    1. Diabetes. 1976 Jan;25(1):65-71
    1. Eur J Clin Invest. 1976 Mar 31;6(2):179-85
    1. Psychopharmacologia. 1976 Apr 15;46(3):295-9
    1. Br Med J. 1976 Jul 31;2(6030):272-3
    1. Br Med J. 1976 Aug 21;2(6033):447-9
    1. Br Med J. 1977 Nov 12;2(6097):1255-7
    1. Lancet. 1979 Mar 3;1(8114):458-62
    1. Drugs. 1979 Mar;17(3):157-60
    1. Biochem J. 1963 Jul;88:137-46
    1. Clin Sci (Lond). 1955 Nov;14(4):639-51
    1. Am J Physiol. 1979 Sep;237(3):E214-23
    1. N Engl J Med. 1980 Aug 21;303(8):436-44
    1. J Clin Invest. 1980 Jul;66(1):94-101
    1. Metabolism. 1980 Sep;29(9):866-72
    1. Br Med J. 1980 Oct 25;281(6248):1143-4
    1. Acta Endocrinol (Copenh). 1980 Nov;95(3):364-71
    1. Acta Endocrinol (Copenh). 1981 Nov;98(3):413-9
    1. Eur J Clin Pharmacol. 1981;21(3):177-84
    1. Br J Clin Pharmacol. 1982;13(Suppl 2):407S-417S
    1. Acta Med Scand. 1982;211(5):381-5
    1. Clin Sci (Lond). 1983 Jan;64(1):49-53
    1. Clin Chem. 1983 Nov;29(11):1923-7
    1. Br J Clin Pharmacol. 1984 Mar;17(3):273-81
    1. Diabetes Care. 1984 May-Jun;7(3):243-7
    1. J Neurosci Methods. 1985 May;13(3-4):239-48
    1. Eur J Clin Pharmacol. 1985;28 Suppl:105-7
    1. Br Med J (Clin Res Ed). 1986 Mar 8;292(6521):647-50
    1. Lancet. 1987 Aug 15;2(8555):359-63
    1. Acta Med Scand. 1987;222(1):57-63
    1. N Engl J Med. 1988 Jul 28;319(4):213-22
    1. Diabetes Care. 1989 Jan;12(1):12-7
    1. Clin Sci. 1967 Aug;33(1):53-65

Source: PubMed

3
Prenumerera